MORABITO, Annunziata
 Distribuzione geografica
Continente #
EU - Europa 241
NA - Nord America 231
AS - Asia 92
SA - Sud America 4
Totale 568
Nazione #
US - Stati Uniti d'America 224
IT - Italia 80
CN - Cina 40
FR - Francia 26
GB - Regno Unito 25
SG - Singapore 24
IE - Irlanda 22
SE - Svezia 20
IN - India 15
NL - Olanda 14
DE - Germania 8
GR - Grecia 7
BA - Bosnia-Erzegovina 6
CA - Canada 4
ES - Italia 4
PL - Polonia 4
RS - Serbia 4
SI - Slovenia 4
BR - Brasile 3
HR - Croazia 3
ID - Indonesia 3
JP - Giappone 3
MX - Messico 3
AT - Austria 2
CH - Svizzera 2
DK - Danimarca 2
FI - Finlandia 2
KR - Corea 2
ME - Montenegro 2
VN - Vietnam 2
AM - Armenia 1
AR - Argentina 1
HK - Hong Kong 1
HU - Ungheria 1
IL - Israele 1
NO - Norvegia 1
RO - Romania 1
UA - Ucraina 1
Totale 568
Città #
Chandler 47
Dublin 22
Singapore 19
Milan 14
Amsterdam 12
Beijing 11
Torino 11
Santa Clara 10
London 9
Rome 9
Turin 9
Nyköping 8
Columbus 7
Fairfield 7
Medford 7
Banja Luka 6
Paris 6
Preveza 6
Princeton 6
Ashburn 5
Chaponost 5
Mumbai 5
Belgrade 4
Brookline 4
Dearborn 4
Guangzhou 4
New York 4
Newcastle upon Tyne 4
Cambridge 3
Chengdu 3
Chennai 3
Coyoacán 3
Genay 3
Hangzhou 3
Houston 3
Hyderabad 3
Jakarta 3
Toulouse 3
Vancouver 3
Villeurbanne 3
Wilmington 3
Zagreb 3
Andover 2
Atlanta 2
Bengaluru 2
Birmingham 2
Celje 2
Dossobuono 2
Flanders 2
Fuzhou 2
Genoa 2
Hebei 2
Jacksonville 2
Lake Villa 2
Lenart v Slov. Goricah 2
Madrid 2
Messina 2
Mutterstadt 2
Nanjing 2
New Delhi 2
Nuremberg 2
Padova 2
Philadelphia 2
Phoenixville 2
Pomezia 2
San Francisco 2
Sevenoaks 2
Shenzhen 2
Stockholm 2
Tarbes 2
Vejle 2
Westfield 2
Woodstock 2
Ann Arbor 1
Boardman 1
Borgaro Torinese 1
Boston 1
Brooklyn 1
Budapest 1
Calgary 1
Cardito 1
Cluj-Napoca 1
Coventry 1
Fano 1
Frattamaggiore 1
Fremont 1
Geneva 1
Guiyang 1
Hellikon 1
Helsinki 1
Hopkins 1
Jaboatao dos Guararapes 1
Kettering 1
Krakow 1
Kunming 1
Lancaster 1
Mannheim 1
Milanówek 1
Norwalk 1
Parma 1
Totale 396
Nome #
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 268
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial 78
ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. 70
International Tailored Chemotherapy Adjuvant (ITACA) Trial, a Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIA Non-Small Cell Lung Cancer 55
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 53
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study 44
Corrigendum: Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study [Front Immunol, 8, (2017), (386)] doi: 10.3389/fimmu.2017.00386 15
Totale 583
Categoria #
all - tutte 2.131
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.131


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202030 0 0 0 0 4 7 7 2 1 3 6 0
2020/202130 0 1 0 1 3 1 1 1 11 3 2 6
2021/202280 2 1 1 5 8 5 5 5 0 8 28 12
2022/2023220 23 21 5 12 18 34 19 19 32 15 14 8
2023/2024144 11 36 14 10 15 15 7 12 1 13 6 4
2024/202556 1 13 7 13 22 0 0 0 0 0 0 0
Totale 583